髓源性抑制细胞——血液肿瘤的免疫治疗靶点  

Myeloid-derived suppressor cells-immunotherapy targets in hematological malignancies

作　　者：刘静静[1] 金财宝 许秀文[1] 朱晓健[1] 孟力[1] 

机构地区：[1]华中科技大学同济医院血液内科,武汉430030

出　　处：《国际肿瘤学杂志》2017年第4期313-316,共4页Journal of International Oncology

基　　金：国家自然科学基金（81272422）

摘　　要：近年来,髓源性抑制细胞（MDSC）成为实体瘤和血液肿瘤的研究热点.在肿瘤中,MDSC不仅通过抑制T细胞增殖、破坏自然杀伤细胞功能和上调调节性T细胞水平发挥免疫抑制作用,还可直接发挥促进肿瘤血管生成和肿瘤转移的非免疫方面的作用.MDSC阻碍了抗肿瘤治疗,尤其影响了免疫治疗的疗效,与临床预后不良相关,可作为肿瘤预后的判断指标,为免疫治疗提供了新靶点.In recent years, the research hot in the field of solid tumor and blood tumor focuses on the myeloid-derived suppressor cells （MDSCs）.In tumors, MDSCs not only exert immunosuppression by inhibiting T cell proliferation, destroying the functions of natural killer cells and recruiting regulatory T cells, but also play non-immunosuppression roles in the promotion of angiogenesis and tumor metastasis.All of these hinder the anti-tumor therapy, and particularly affect the curative effect, which are related with a poor clinical prognosis.MDSCs can be used as prognostic markers, which provide new targets for immunotherapy.

关 键 词：免疫抑制剂 治疗 髓源性抑制细胞 

分 类 号：R733[医药卫生—肿瘤]